Hormonal substrate — testosterone, estrogen, prolactin, thyroid

What actually decides this outcome, in order of size

Desire is the outcome, and hormones are one of its inputs rather than its definition. Ranked by how much of the outcome each one owns:

1. Where the baseline sits, because the benefit is a function of it. An individual participant data meta-analysis examined symptomatic benefit from testosterone treatment across patient subgroups rather than as a single average Hudson 2023. That design is the whole argument of this page: the same treatment produces different effects in different starting states, and the average is nobody's result.
2. Whether the low concentration is real or the assay is. Testosterone below the reference limit on one morning draw is common and frequently not reproduced on a second. Estradiol is worse: an Endocrine Society position statement set out the measurement problem directly Rosner 2013, and men's concentrations sit at the end of the range where immunoassays are least reliable.
3. Prolactin and thyroid, which the page's own introduction names as the two commonest misses. They are cheap, they are one draw, and a raised prolactin has a specific analytic trap: cross-reactivity with macroprolactin means a proportion of raised results are not biologically active hormone, and screening policy for it has been examined in its own right Smith 2022. Treating an untriaged high prolactin is how somebody ends up on a dopamine agonist for a laboratory artifact.
4. What the treatment actually moved, when it was measured properly. Testosterone replacement improved sexual function and hypogonadal symptoms in men with hypogonadism in a randomized setting Pencina 2023. That is a real effect in a defined population, and the population is the operative half of the sentence.
5. The botanicals, last, and their effect sizes are not in the same units as the pharmacology. Cistanche has a randomized, double-blind, placebo-controlled study Chen 2024. That is more than most of this shelf has and it is still not a hormone.

The order to run these in, and what has to be true first

Two draws before any decision, the cheap exclusions before the expensive hypothesis, and the prescription arm through a prescriber. The order exists because the two commonest causes on this page are also the two cheapest to exclude.

1. Prolactin and TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) first, on the page's own logic. Hyperprolactinemia suppresses gonadotropin pulsatility and blunts desire directly; hypothyroidism does both indirectly. If prolactin is high, the next step is a repeat under standardized conditions and a macroprolactin assessment rather than a treatment Smith 2022.
2. Two morning Total Testosterone draws with SHBG (Sex Hormone-Binding Globulin), not one. Testosterone is pulsatile and diurnal, and a single low value is a common finding in men who are fine. Free Testosterone and Estradiol, Sensitive (LC/MS-MS) complete the picture, and the sensitive assay is the one that survives Rosner 2013. LH & FSH separates a testis problem from a pituitary one, which decides everything below.
3. Exclude the boring causes in the same draw. Ferritin for iron deficiency, HbA1c (Hemoglobin A1c) for undiagnosed diabetes, Comprehensive Metabolic Panel (CMP) for renal and hepatic function. Each of these produces low desire on its own and each is treatable without touching an androgen.
4. Audit the medication list before adding to it. Serotonergic antidepressants, finasteride and dutasteride, opioids, beta-blockers and several antihypertensives all reduce desire, and the person to have that conversation with is the prescriber. This step is free and it is the one most often skipped.
5. Enclomiphene and HCG are the fertility-preserving arm and they are prescription decisions. Enclomiphene raises endogenous testosterone while preserving sperm parameters that exogenous androgen suppresses Wiehle 2014, and the suppression of spermatogenesis caused by exogenous testosterone is the specific problem that arm exists to avoid Desai 2022. Gonadorelin and Kisspeptin sit upstream of both and are argued at Upstream stimulation — keeping the axis running.
6. Anastrozole and Cabergoline are corrections, not enhancements. An aromatase inhibitor lowers estradiol, and estradiol in men is required for libido and for bone; driving it down in a man with a normal value predictably makes desire worse. That trade-off is argued at Aromatase & estrogen management. Cabergoline belongs to a confirmed and triaged hyperprolactinemia only.
7. DHEA and Pregnenolone are precursors with a measurable effect on the products. Supplementation shifts testosterone and estradiol measurably He 2025, which is precisely why they are not a casual purchase in anybody with a hormone-sensitive history.
8. The botanical shelf last, judged individually. Cistanche has the randomized study Chen 2024; Vitex (Chasteberry) is a prolactin-directed plant with European self-medication history Hoshino 2018 and a dopaminergic mechanism Puglia 2023, which makes it a poor idea alongside a dopamine agonist. Tongkat Ali, Shilajit, Fenugreek, Boron, Zinc, Royal Jelly and Thyroid Support are judged on the same standard.

What gets bought for this that cannot move it

The category that fails is the testosterone booster bought by a man with a normal testosterone. If the axis is intact and the concentration is mid-range, there is no deficit for a precursor or a secretagogue to correct, and the subgroup analysis is the evidence for that rather than an opinion Hudson 2023. This is the single commonest purchase made from this page and the one with the lowest prior probability of doing anything.

The aromatase inhibitor is the option here most likely to make the problem worse. Estradiol is not a contaminant in men. It is required for libido, for bone mineral density and for normal sexual function, and the measurement difficulties at male concentrations mean the number someone is treating is often not the number they have Rosner 2013. Suppressing it on the strength of one immunoassay result is a plausible route to the exact symptom the reader came with.

And a hormone panel cannot answer a relationship or a situational question. Desire that is absent with a long-term partner and present otherwise, desire that disappeared with a life event, and desire suppressed by a medication are all common and none of them has a laboratory correlate. A page of seventeen products that does not say so is inviting a man to run an endocrine investigation on a problem that was never endocrine.

If the pattern is different, so is the page. Desire intact but erections unreliable is Vascular & erectile function. Desire absent with everything else absent too is Central desire — melanocortin & dopaminergic. Exhausted, stressed and not interested is Stress, sleep and the things that quietly kill desire. A prolactin that is genuinely high on a repeat draw needs imaging of the pituitary, which is a clinician and not a supplement.

How you would know it was working, on a real read-out and a real timescale

The prediction this page makes is that correcting a genuinely low value should move desire within one to two months, and that correcting a normal value should move nothing. If the markers change and the symptom does not, the hormone was not the cause, and that is a finding worth more than another product.

• Two morning Total Testosterone draws with SHBG (Sex Hormone-Binding Globulin) before anything, and again at 8 to 12 weeks. Two because a single low result is frequently not reproduced, and morning because the diurnal peak is what the reference intervals were built on. Eight weeks because that is roughly when the symptomatic separation appeared in the randomized sexual function work Pencina 2023.
• Prolactin repeated before it is treated. Prolactin rises with stress, with a difficult venepuncture, with sleep and after orgasm, and a proportion of raised values are macroprolactin rather than active hormone Smith 2022. One value has never been a diagnosis.
• Estradiol, Sensitive (LC/MS-MS) rather than the standard assay, and only with a reason. The measurement problem at male concentrations is documented Rosner 2013, and an estradiol drawn without a specific question is the most likely marker on this page to trigger an unnecessary intervention.
• TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) and Ferritin once, to be normal. A normal set here closes two of the four causes the page names in its own title and costs less than one month of most of the shelf.
• A weekly count, not a feeling. Number of days with spontaneous desire in the last seven. It is the only endpoint on this page that measures what the reader actually came for, and the trials used structured symptom instruments for the same reason Hudson 2023.

What will fool you. Testosterone falls with acute illness, with poor sleep and with energy deficit, so a low value drawn in a bad month describes the month. Starting a supplement usually coincides with sleeping more and drinking less, which move the same numbers. Enclomiphene and hCG raise the measured hormone reliably, which makes the laboratory look successful whether or not desire changed Wiehle 2014. And a DHEA product will raise downstream androgens measurably He 2025, so a rising testosterone in somebody taking it is confirming the biochemistry rather than the benefit.

Sources read for these sections

• Hudson J. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis. Lancet Healthy Longevity 2023 · PMID 37804846
• Pencina KM. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. Journal of Clinical Endocrinology and Metabolism 2023 · PMID 37589949
• Smith TP, et al. Cross-reactivity in assays for prolactin and optimum screening policy for macroprolactinaemia. Clinical Chemistry and Laboratory Medicine 2022 · PMID 35708266
• Rosner W, et al. Challenges to the measurement of estradiol: an endocrine society position statement. Journal of Clinical Endocrinology and Metabolism 2013 · PMID 23463657
• Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone (ZA-203, NCT01270841).. Fertil Steril 2014 · PMID 25044085
• Desai A, et al. Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS). Therapeutic Advances in Urology 2022 · PMID 35783920
• Puglia LT. Vitex agnus castus effects on hyperprolactinaemia. Front Endocrinol (Lausanne) 2023 · PMID 38075075
• Chen L, et al. A randomized, double-blind, placebo-controlled study of Cistanche tubulosa and Ginkgo biloba extracts for the improvement of cognitive function in middle-aged and elderly people. Phytotherapy Research 2024 · PMID 38972848
• He S, et al. Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects. Diabetology and Metabolic Syndrome 2025 · PMID 40616152
• Hoshino T. European Ethnopharmaceuticals for Self-Medication in Japan: Review Experience of Vitis vinifera L., Folium Extract and Vitex agnus-castus L., Fructus Extract as OTC Drugs. Medicines (Basel) 2018 · PMID 29316611